Prevalence of potential proton-pump inhibitor drug interactions: A retrospective review of prescriptions in community pharmacies

Clinical Therapeutics

Volumn 21, Issue 10, 1999, Pages 1812-1819

  Saltiel, Emmanuel ^a   Fask, Alan ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

Author keywords

Drug interactions; Lansoprazole; Omeprazole; Proton pump inhibitor

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLONAZEPAM; CLORAZEPATE; CYCLOSPORIN; DIAZEPAM; DISULFIRAM; ESTAZOLAM; FLURAZEPAM; HALAZEPAM; LANSOPRAZOLE; MIDAZOLAM; OMEPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; QUAZEPAM; SUCRALFATE; THEOPHYLLINE; TRIAZOLAM; WARFARIN;

ARTICLE; CLINICAL PRACTICE; DRUG ABSORPTION; HUMAN; PHARMACY; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; STOMACH PH;

EID: 0032692836     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80059-9     Document Type: Article

References (35)

1. 1. Johnson JA, Bootman JL. Drug-related morbidity and mortality: A cost-of-illness model. Arch Intern Med. 1995;155:1949-1956.
2. 2. Griffin JW, May JR, DiPiro JT. Drug interactions: Theory versus practice. Am J Med. 1984;77(Suppl 5B):85-89.
3. 3. Hansten PD, Horn JR. Hansten and Horn's Drug Interactions Analysis and Management. Vancouver, BC, Canada: Applied Therapeutics Inc; 1997.
4. 4. Grasela TH Jr, Dreis MW. An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration Spontaneous Reporting System. Arch Intern Med. 1992;152:617-621.
5. 5. des Varannes SB, Levy P, Lartigue S, et al. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther. 1994; 8:309-314.
6. 6. Tolman KG, Sanders SW, Buchi KN, et al. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol. 1997;24:65-70.
7. 7. Florent C, Forestier S, Joubert-Collin M. Lansoprazole versus omeprazole: Efficacy and safety in acute gastric ulcer. Gastroenterology. 1993;104:A80. Abstract.
8. 8. Castell DO, Richter JE, Robinson M, et al, and the Lansoprazole Group. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol. 1996;91:1749-1757.
9. 9. Humphries TJ. Clinical implications of drug interactions with the cytochrome P-450 enzyme system associated with omeprazole. Dig Dis Sci. 1991;36:1665-1669.
10. 10. Physicians' Desk Reference®. 52nd ed. Montvale, NJ: Medical Economics Company; 1998:331,2921.
11. 11. Reilly PEB, Thompson DA, Mason SR, et al. Cytochrome P450IIIA enzymes in rat liver microsomes: Involvement in C3-hydroxylation of diazepam and nordazepam but not N-dealkylation of diazepam and temazepam. Mol Pharmacol. 1990;37:767-774.
12. 12. Abernethy DR, Greenblatt DJ, Morse DS, et al. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. Br J Clin Pharmacol. 1985;19:51-57.
13. 13. Sonne J, Andreasen PB, Loft S, et al. Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. Hepatology. 1990;11:951-956.
14. 14. Ruffalo RL, Thompson JF, Segal JL. Diazepam-cimetidine drug interactions: A clinically significant effect. South Med J. 1981;74:1075-1078.
15. 15. Lefebvre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther. 1992;52:458-463.
16. 16. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Gastroenterology. 1985;89:1235-1241.
17. 17. Andersson T, Andren K, Cederberg C, et al. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol. 1990;39:51-54.
18. 18. Martí-Massó JF, Lòpez de Munain A, Lòpez de Dicastillo G. Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction. Ann Pharmacother. 1992;26:429-430.
19. 19. Hobbs WR, Rall TW, Verdoorn TA. Hypnotics and sedatives; ethanol. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:361-396.
20. 20. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther. 1996;59:514-519.
21. 21. Kronbach T, Mathys D, Umeno M, et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol. 1989;36:89-96.
22. 22. Nims RW, Prough RA, Jones CR, et al. In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam. Drug Metab Dispos. 1997;25:750-756.
23. 23. Mukherji D, Cavanaugh JH. Lack of effect of concomitant multi-dose lansoprazole on single-dose phenytoin pharmacokinetics in subjects. Gastroenterology. 1994;106:A103. Abstract.
24. 24. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol. 1987;24:543-545.
25. 25. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet. 1996;31: 9-28.
26. 26. Braechman RA, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on warfarin pharmacokinetics and anticoagulation effect in healthy subjects. Pharmacol Res. 1991;8(Suppl 10):S295. Abstract.
27. 27. Cavanaugh JH, Winters EP, Cohen A, et al. Lack of effect of lansoprazole on steady-state warfarin metabolism. Gastroenterology. 1991;100:A40. Abstract.
28. 28. Sutfin T, Balmer K, Bostrom N, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit. 1989;11:176-184.
29. 29. Ahmad S, Omeprazole-warfarin interaction. South Med J. 1991;84:674-675. Letter.
30. 30. Granneman GR, Karol MD, Locke CS, Cavanaugh JH. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit. 1995;17:460-464.
31. 31. Roux A, Naline R, Molinier P, et al. Effect of lansoprazole and omeprazole on the metabolism of theophylline and antipyrine in man. Eur J Drug Metab Pharmacokinet. 1993;18:125. Abstract.
32. 32. Zimmermann AE, Katona BG. Lansoprazole: A comprehensive review. Pharmacotherapy. 1997;17:308-326.
33. 33. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet. 1991; 21:195-212.
34. 34. Schouler L, Dumas F, Couzigou P, et al. Omeprazole-cyclosporin interaction. Am J Gastroenterol. 1991;86:1097. Letter.
35. 35. Reichenspurner H, Meiser BM, Muschiol F, et al. The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: Experimental and clinical results. J Heart Lung Transplant. 1993;12:987-992.